DENVER – Colorado’s new Daniel Bregger Act is reshaping the conversation around kratom by tightening safety rules without banning the herbal supplement that many users credit with easing pain and opioid withdrawal. The law caps highly concentrated 7-hydroxymitragynine products, restricts sales to adults over 21 and requires clearer labeling, moves designed to steer consumers toward traditional leaf-based kratom and away from risky gas-station style shots.
Researchers, backed by multimillion-dollar NIH funding, are simultaneously probing kratom’s alkaloids as candidates for safer pain medicines and treatments for opioid dependence. Early work suggests some compounds may relieve pain and withdrawal with less danger of respiratory depression, strengthening calls to regulate, not prohibit, kratom. A fuller exploration of these developments appears in The Conversation’s analysis.